Literature DB >> 9734608

IgA induced activation of human mesangial cells: independent of FcalphaR1 (CD 89).

S C Diven1, C R Caflisch, D K Hammond, P H Weigel, J A Oka, R M Goldblum.   

Abstract

BACKGROUND: IgA nephropathy (IgAN) is characterized by deposition of polymers of IgA1 in the mesangium, accumulation of mesangial matrix and mesangial cell proliferation. Activation of the mesangial cell by IgA, via an IgA receptor, may be an initiating event in the pathology of IgAN.
METHODS: We examined the ability of radiolabeled, normal serum IgA1 to bind human mesangial cells (HMC). Activation of HMC by monomeric (mIgA1) and heat aggregated IgA1 (AIgA1) was compared by Northern analysis of c-jun expression. The expression of FcalphaR1 (CD89) mRNA on our cultured mesangial cells was also assessed by Northern analysis, reverse transcription-polymerase chain reaction (RT-PCR) and flow cytometry.
RESULTS: 125I-mIgA1 and 125I-AIgA1 bound to HMC in a dose-dependent, saturable manner with similar affinities. There were 1.2 x 10(6) binding sites per cell, with an affinity constant of 2.3 x 10(6) M(-1). AIgA1 induced c-jun expression in a time and dose-dependent manner (2.4-fold above baseline after 60 min exposure to AIgA1 200 microg/ml) while mIgA1 had no effect on c-jun expression. No message for CD 89 was detectable in quiescent or AIgA1 stimulated HMC by Northern analysis or RT-PCR using several primer sequences based on the sequence of U937 FcalphaR cDNA. Flow cytometry on the mesangial cells, using My 43, a monoclonal antibody to FcalphaR1 confirmed that CD 89 was not present on the cell.
CONCLUSION: These results demonstrate that HMC bind mIgA1 and AIgA1 with similar affinity. However, activation of HMC requires an aggregated form of IgA1. These processes are independent of FcalphaR1, suggesting the presence of a new IgA receptor on mesangial cells.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9734608     DOI: 10.1046/j.1523-1755.1998.00054.x

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  10 in total

Review 1.  Progress in molecular and genetic studies of IgA nephropathy.

Authors:  J Novak; B A Julian; M Tomana; J Mesteck
Journal:  J Clin Immunol       Date:  2001-09       Impact factor: 8.317

Review 2.  Pathogenesis of IgA nephropathy.

Authors:  Kar Neng Lai
Journal:  Nat Rev Nephrol       Date:  2012-03-20       Impact factor: 28.314

3.  Differential binding characteristics of native monomeric and polymeric immunoglobulin A1 (IgA1) on human mesangial cells and the influence of in vitro deglycosylation of IgA1 molecules.

Authors:  Y-H Gao; L-X Xu; J-J Zhang; Y Zhang; M-H Zhao; H-Y Wang
Journal:  Clin Exp Immunol       Date:  2007-03-26       Impact factor: 4.330

4.  Self-aggregated deglycosylated IgA1 with or without IgG were associated with the development of IgA nephropathy.

Authors:  Y Yan; L-X Xu; J-J Zhang; Y Zhang; M-H Zhao
Journal:  Clin Exp Immunol       Date:  2006-04       Impact factor: 4.330

5.  Binding capacity and pathophysiological effects of IgA1 from patients with IgA nephropathy on human glomerular mesangial cells.

Authors:  Y Wang; M-H Zhao; Y-K Zhang; X-M Li; H-Y Wang
Journal:  Clin Exp Immunol       Date:  2004-04       Impact factor: 4.330

6.  Fcalpha receptor (CD89) mediates the development of immunoglobulin A (IgA) nephropathy (Berger's disease). Evidence for pathogenic soluble receptor-Iga complexes in patients and CD89 transgenic mice.

Authors:  P Launay; B Grossetête; M Arcos-Fajardo; E Gaudin; S P Torres; L Beaudoin; N Patey-Mariaud de Serre; A Lehuen; R C Monteiro
Journal:  J Exp Med       Date:  2000-06-05       Impact factor: 14.307

7.  Identification of the transferrin receptor as a novel immunoglobulin (Ig)A1 receptor and its enhanced expression on mesangial cells in IgA nephropathy.

Authors:  I C Moura; M N Centelles; M Arcos-Fajardo; D M Malheiros; J F Collawn; M D Cooper; R C Monteiro
Journal:  J Exp Med       Date:  2001-08-20       Impact factor: 14.307

Review 8.  The Origin and Activities of IgA1-Containing Immune Complexes in IgA Nephropathy.

Authors:  Barbora Knoppova; Colin Reily; Nicolas Maillard; Dana V Rizk; Zina Moldoveanu; Jiri Mestecky; Milan Raska; Matthew B Renfrow; Bruce A Julian; Jan Novak
Journal:  Front Immunol       Date:  2016-04-12       Impact factor: 7.561

9.  Functional networks of aging markers in the glomeruli of IgA nephropathy: a new therapeutic opportunity.

Authors:  Hong Jiang; Ludan Liang; Jing Qin; Yingying Lu; Bingjue Li; Yucheng Wang; Chuan Lin; Qin Zhou; Shi Feng; Shun H Yip; Feng Xu; En Yin Lai; Junwen Wang; Jianghua Chen
Journal:  Oncotarget       Date:  2016-06-07

10.  Pathogenic role of glycan-specific IgG antibodies in IgA nephropathy.

Authors:  Yan-Feng Zhao; Li Zhu; Li-Jun Liu; Su-Fang Shi; Ji-Cheng Lv; Hong Zhang
Journal:  BMC Nephrol       Date:  2017-09-29       Impact factor: 2.388

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.